文献速递神经肿瘤

理性乐观:儿童低级别胶质瘤精准医学时代的进展

Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma.
PubMed 文献 · Neuro Oncol · 2026-01-01

本文由国际pLGG联盟临床工作组撰写,讨论儿童低级别胶质瘤分子靶向治疗格局,指出尽管临床试验众多,仅两种口服精准方案获联邦机构批准,早期试验结果导致超适应症处方增加,但缺乏3期数据和长期疗效安全性认知,强调耐心与循证实践。

要点

  • 仅两种口服精准方案获联邦批准用于pLGG。
  • 早期试验结果推动超适应症处方,但缺乏3期证据。
  • 长期影像、功能结局和毒性认知不完整,需谨慎。

核心结论

  • pLGG靶向治疗需耐心和循证实践,避免过早超适应症使用。

研究设计与样本

  • 国际pLGG联盟临床工作组撰写的社论,综述靶向治疗证据。

主要发现

  • 众多临床试验仅两种口服精准方案获联邦批准。
  • 早期试验结果导致超适应症处方增加。
  • 缺乏3期数据和长期影像、功能及毒性认知。

临床怎么用

  • 选择pLGG治疗时应考虑知识缺口,预防和减少远期后遗症。
  • 超适应症使用靶向药需权衡风险与获益。

局限性

  • 缺乏3期临床试验数据和长期结局认知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical trial landscape of molecularly targeted treatments for pediatric low-grade glioma (pLGG) has created an exciting and hopeful era for both patients and clinicians alike. Despite numerous clinical trials investigating the use of targeted agents for pLGG, only two oral precision-based regimens for pLGG have received federal agency approval. However, enthusiasm surrounding recently completed early phase clinical trials has resulted in increased off-label prescribing practices beyond the federally-approved indications, despite a lack of phase 3 clinical trial data and an incomplete understanding of the long-term radiographic, functional outcomes, and toxicity for both approved and experimental therapies. These gaps in knowledge are critically important to consider when selecting therapies for patients with pLGG, as the prevention and reduction of late effects in pLGG survivors is crucial to prevent long-term morbidity. In this editorial by the clinical working group of the International pLGG Coalition, we discuss the landscape of molecularly targeted therapies for pLGG, outline the unanswered questions for the use of novel therapies in the management of pLGG, review the risks and benefits of early off-label use of targeted agents, and discuss the importance of patience and evidence-based clinical practice in the rapidly evolving era of precision medicine. There is growing excitement about new targeted therapies for the treatment of pediatric lowgrade glioma (pLGG). However, only two of these targeted treatments have received regulatory approval, despite many being studied in clinical trials. Promising early clinical trial results from small studies have led some clinicians to prescribe these targeted therapies without regulatory approval. This raises concerns, as important questions remain about the long-term effectiveness and safety of these new medications. These knowledge gaps are especially important to consider in pLGG, as many children survive after diagnosis. This manuscript provides an evidence-focused review of targeted therapies for pLGG, with a specific emphasis on current knowledge gaps, the risks and benefits of prescribing these therapies without regulatory approval, and the importance of patience in clinical practice.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kotch C, Perreault S, Power P, et al. Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma. Neuro Oncol. 2026. PMID: 42155029. doi:10.1093/neuonc/noag111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。